Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational...
discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(11)
•••
garygp
X
View Profile
View Bullboard History
Comment by
garygp
on Jul 31, 2024 12:34pm
RE:Sphera / Blackrock
It appears to me that the average shareholder is cooked with the direction we would like to have seen the company taken. The direction we go now is clearly in the hands of Sphera. Even the
...more
(198)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Jul 31, 2024 12:30pm
Due diligence
For those of you who follow PMN, I am not here to do all the due diligence for you and you should do your own. In the previous financing who sold over 13 million shares in one day when the total
...more
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jul 31, 2024 6:16am
RE:Orchestrated selling
"The selling at a loss is done by Sphera who made over 80 million dollars shorting Promis illegally and getting away with it." Where do you get such information? G1945V
(36)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jul 30, 2024 6:55pm
RE:Orchestrated selling
Interesting claim, looking forward to the details. Please indulge us.
(198)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Jul 30, 2024 6:03pm
Sphera / Blackrock
https://sphera.com/company/who-we-are/
(198)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Jul 30, 2024 3:37pm
Orchestrated selling
The selling at a loss is done by Sphera who made over 80 million dollars shorting Promis illegally and getting away with it. Besides their previous warrants and the current placement, they own Promis
...more
(36)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jul 30, 2024 1:38pm
RE:RE:RE:RE:RE:RE:RE:New Press Release - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
Agreed, but dilution was an objective, otherwise the major shareholders would not have run the price down to $2 in the first place. That's why I said clever.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 30, 2024 8:30am
New Press Release - ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer’s disease vaccine CAMBRIDGE, Massachusetts and TORONTO, Ontario, July 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...
read article.
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jul 30, 2024 5:54am
RE:RE:RE:RE:RE:RE:New Press Release - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
Convertible debentures would have been a better choice paying a reasonable interest rate with a reasonable maturity date. A less dilutive option if we are to believe that the share price will increase
...more
(36)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jul 29, 2024 10:51pm
RE:Think About This.
Of course the market has it wrong. Like everything else "Brought to you by Pfizer".
(61)
•••
bball67
X
View Profile
View Bullboard History
Comment by
bball67
on Jul 29, 2024 10:03pm
RE:RE:RE:Financing explanation?
So, Promis will be releasing blood biomarker results after six months of PMN 310. Why, because they are a major tell on what the clinical results will be. They are breaking new ground. So, the
...more
(20)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Comment by
FarmerBetsy
on Jul 29, 2024 8:13pm
RE:RE:Financing explanation?
How do they plan on doing this 6 month interim data when the alzheimers trials are Randomized, double-blind, placebo-controlled study? What other trial has 6 month interim data? Bristol Myers
...more
(61)
•••
bball67
X
View Profile
View Bullboard History
Post by
bball67
on Jul 29, 2024 7:54pm
Think About This.
Market Cap at close today a little more than $30M. New cash at closing $30M. Value of Entity and intellectual property is ZERO. Does that make any sense? The entity valuation was $40M+ a week ago with
...more
(61)
•••
bball67
X
View Profile
View Bullboard History
Comment by
bball67
on Jul 29, 2024 7:20pm
RE:RE:RE:RE:New Press Release - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
There he goes again. Remember when Farmer said they would NEVER enter clinical trials. Well they will start 1b in 2-3 months. Exactly how many employees do you need to get to "organizational
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences